New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
19:19 EDTLLYEli Lilly, BIPI announce results of two Phase lll clinical trials
Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes, T2D, Boehringer Ingelheim Pharmaceuticals, BIPI, and Eli Lilly and Company announced. The findings were presented as late breaking abstracts at the American Diabetes Association 74th Scientific Sessions. The 24-week primary findings of these two 52-week trials compared the combination of empagliflozin and linagliptin with empagliflozin or linagliptin alone in patients with T2D and moderately elevated blood glucose levels consistent with what is often seen in clinical practice.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
10:32 EDTLLYFDA approvals Synjardy tablets for adults with Type 2 diabetes
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate new Phase 1b study of BioChaperone Lispro
Subscribe for More Information
August 25, 2015
17:11 EDTLLYU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
August 20, 2015
13:26 EDTLLYOn The Fly: Top stock stories at midday
Subscribe for More Information
11:33 EDTLLYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information
August 18, 2015
10:01 EDTLLYEli Lilly says Humalog 200 units/mL KwikPen available in U.S. pharmacies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use